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Fibrinogen fragments and platelet dysfunction in uremia. stimulation by various aggregating agents [4, 5]. Although
Background. The uremic state is characterized by subnor- the mechanisms of this hyporesponsiveness have not been
mal platelet aggregation. Fibrinogen fragments, usually absent fully delineated, it appears that abnormalities in bothin normal human blood, but present in uremic plasma, may
the platelets and the plasma play a role. Plasma abnor-play a role in uremic platelet dysfunction.
malities that contribute to the impaired platelet aggrega-Methods. To examine this hypothesis, we investigated the
availability and function of fibrinogen receptors [glycoprotein tion in uremia are multifactorial. Urea [5, 6] and other
(GP) IIb-IIIa] on uremic and normal platelets, as well as the nitrogenous compounds, such as guanidinosuccinic acid
effect of fragments obtained from chymotrypsin digestion of
[7], phenols [8], and a group of substances subsumedhuman fibrinogen on normal platelets. The availability of fi-
under uremic middle molecules [9] have been incrimi-brinogen receptors was examined using anti-GP IIb-IIIa anti-
bodies and flow cytometry, whereas receptor function was as- nated in the decreased platelet aggregation in platelet-
sessed by the receptor’s ability to mediate fibrinogen binding rich plasma (PRP) in vitro.
and platelet aggregation. Another plasma factor that has been recently suggestedResults. Platelet aggregation and the availability of GP IIb-
to decrease platelet aggregation in uremia is fragments ofIIIa were lower in uremic patients when compared with normal
fibrinogen. In the normal clotting process, the adhesivecontrols. Flow cytometric analysis showed that fibrinogen frag-
ments decreased the binding of anti-CD61, an activation-inde- protein fibrinogen forms a bridge between activated
pendent anti-GP IIIa monoclonal antibody, to resting normal platelets by binding to the glycoprotein IIb-IIIa complex
platelets. These fragments also reduced the binding of PAC-1, an (GP IIb-IIIa) on the cytoplasmic membrane surface ofactivation-dependent anti-GP IIb-IIIa monoclonal antibody, to
adjacent cells [10]. As a result of multiple interactionsadenosine diphosphate (ADP)-activated normal platelets. In
of this type, platelet aggregates are formed. Recent stud-addition, the binding of radiolabeled fibrinogen to activated
normal platelets and platelet aggregation in response to ADP ies by Sreedhara, Itagaki, and Hakim have demonstrated
were both decreased by fibrinogen fragments. that fibrinogen fragments are present in uremic plasma,
Conclusions. These findings suggest that fibrinogen frag-
but not in normal human blood [11]. It has been hypothe-ments impair platelet function by occupying fibrinogen recep-
sized that these fibrinogen fragments in uremic plasmators prior to cell activation, thus preventing the binding of
intact fibrinogen to platelets after subsequent stimulation. These may occupy some of the GP IIb-IIIa sites on the platelet
observations also suggest a plausible mechanism by which en- membrane, thus preventing the binding of intact fibrin-
dogenous fibrinogen fragments present in uremic plasma may ogen and cross-linking between adjacent platelets to
contribute to platelet dysfunction.
form aggregates [11]. The aim of this study was to investi-
gate the effect of fibrinogen fragments on the availability
of platelet surface fibrinogen receptors and on platelet
Subnormal platelet function has been implicated in the aggregation in order to gain insight into the potential
hemostatic defect in uremia [1–3]. Specifically, uremic role that endogenous fibrinogen fragments may play in
platelets have been shown to be poorly responsive to platelet dysfunction in uremic patients.
Key words: chronic renal failure, flow cytometry, platelet aggregation, METHODS
uremic platelet, clotting.
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alter platelet function within the previous 14 days. Blood determined using an extinction coefficient at 280 nm of
was drawn into Vacutainer tubes (Becton Dickinson, 1.55. The fibrinogen fragment preparations were ana-
Rutherford, NJ, USA) containing 3.2% trisodium citrate lyzed by sodium dodecyl sulfate-polyacrylamide gel elec-
in a ratio of citrate:whole blood of 1:9 (vol/vol). Blood trophoresis (SDS-PAGE) [13] under nonreducing condi-
from chronic hemodialysis patients was drawn from the tions using 10% gels and staining with Coomassie Blue.
arteriovenous fistula predialysis prior to the administra-
Measurement of platelet aggregationtion of heparin. In the control group, blood was obtained
by venipuncture of an antecubital vein. An aggregation of platelets in PRP or GFP was in-
The specimen was immediately taken to the laboratory duced by incremental concentrations (0 to 20 mm) of
where PRP was obtained by centrifugation of whole adenosine diphosphate (ADP; Sigma Chemical Co.) at
blood at 100 3 g for 15 minutes, and platelet-poor plasma 378C in separate tubes containing a reaction volume of
(PPP) was prepared by centrifugation of the remaining 500 ml. Platelet aggregation was recorded as an increase
blood at 1000 3 g for an additional 10 minutes at 228C. in light transmission occurring following the addition of
Platelet counts for experiments were adjusted to a final ADP in a dual sample aggregometer (DP-247F; Sienco
concentration of 2.5 3 108 per ml by mixing appropriate Inc., Morrison, CO, USA). Aggregation was quantitated
ratios of PRP and homologous PPP. by the area under the aggregation curve from zero to
Gel-filtered platelets (GFP) were prepared from PRP three minutes.
by a modification of the procedure described previously The effect of fibrinogen fragments on platelet aggrega-
[12]. Briefly, 14 ml of Sepharose 2B (Sigma Chemical tion was examined using both PRP and GFP. Normal
Co., St. Louis, MO, USA) were packed in a 20 ml column, PRP was incubated for 20 minutes at 378C with fibrino-
rinsed with distilled water, and equilibrated with saline gen fragments (2.5 mg/ml). Alternatively, normal GFP
at 228C. Two milliliters of PRP were applied to the col- was incubated for 10 minutes at 378C with fibrinogen
umn and eluted with saline. The effluent platelets were fragments (2.0 mg/ml) that had been depleted of intact
collected in a glass tube. This procedure separates plate- fibrinogen. Using fragment preparations that had been
lets from practically all plasma proteins, including fi- depleted of intact fibrinogen in experiments with PRP
brinogen. Prior to aggregation studies, fibrinogen (6.2 would have been superfluous because the plasma con-
mg/ml; Calbiochem-Novabiochem, La Jolla, CA, USA), tained a large amount of fibrinogen. Substitution of fi-
glucose (1 mg/ml), and CaCl2 (0.05 mm) were added to brinogen fragments with saline served as controls. Plate-
the GFP. let aggregation in these inhibition experiments was
induced by the addition of a threshold dose of ADP,Preparation of fibrinogen fragments
which is defined as the minimum dose of ADP requiredLyophilized agarose beads with 100 units of immobi-
to produce maximal aggregation in control samples.lized a-chymotrypsin (chymotrypsin beads; Sigma Chemi-
cal Co.) were washed first with distilled water and then Flow cytometric analysis of platelet surface
with phosphate-buffered saline (PBS; consisting of 0.1 fibrinogen receptor
m sodium phosphate and 0.145 m NaCl, pH 7.3). Two
Glycoprotein IIb-IIIa is a heterodimer on normalmilliliters of fibrinogen (25 mg/ml; Calbiochem-Novabio-
platelet surface that serves as the primary fibrinogenchem) in PBS were incubated with the chymotrypsin
receptor for platelet aggregation. The expression of GPbeads (100 units) for 30 minutes at 228C to generate
IIIa on resting normal and uremic platelets was analyzedfibrinogen fragments. The beads were then removed by
by flow cytometric analysis using fluorescein isothiocya-centrifugation at 1000 3 g for five minutes twice.
nate (FITC)-conjugated monoclonal antibody againstFor some experiments described later in this article,
GP IIIa (anti-CD61; Sigma Chemical Co.). Platelets (106the intact fibrinogen was removed from the fibrinogen
cells) in normal or uremic PRP were diluted in 100 mlfragment preparation using gel filtration as follows. After
of PBS. The samples were incubated with saturatingpassing through a 0.45 mm filter, the fibrinogen fragment
concentrations of FITC-conjugated anti-CD61 at 228Cpreparation was applied to a Superdex 75 HiLoad 26/60
for 25 minutes in the dark. At the end of incubation,column (Pharmacia, Uppsala, Sweden) that had been
platelets were washed twice and then resuspended inequilibrated with 0.15 m NaCl. Gel filtration was per-
500 ml of 1% paraformaldehyde (pH 7.3) at 48C.formed at a flow rate of 1 ml/min, and 5 ml fractions
To determine the effect of fibrinogen fragments onwere collected. A protein concentration in the fractions
GP IIIa expression on resting normal platelets, 106 plate-was monitored by spectrophotometric absorbance at 280
lets in PRP were incubated with fibrinogen fragments (4nm. Fractions from each protein peak were pooled and
mg/ml) and CaCl2 (0.04 mm) at 228C for 20 minutesconcentrated using an Amicon concentrator equipped
without agitation. PRP incubated with PBS instead ofwith a PM-10 membrane (Amicon, Beverly, MA, USA).
The final protein concentration of the preparations was fibrinogen fragments served as a control. The expression
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of GP IIIa on platelet surfaces was subsequently detected
by FITC-conjugated anti-CD61.
In addition to resting platelets, the effect of fibrinogen
fragments on GP IIb-IIIa expression on activated normal
platelets was also examined using flow cytometry. Plate-
lets in citrated whole blood were incubated with fibrino-
gen fragments (4 mg/ml) or PBS in the presence of CaCl2
(0.04 mm) and were then stimulated with ADP (10 mm)
as described earlier in this article. The samples were
then incubated with a saturating concentration of FITC-
conjugated PAC-1 (Becton Dickinson). After fixation in
paraformaldehyde, the samples were subjected to flow
cytometric analysis. PAC-1 is a monoclonal antibody
against human platelet GP IIb-IIIa. In contrast to anti-
CD61, which detects both unactivated and activated GP
IIIa, PAC-1 is specific for GP IIb-IIIa on activated plate-
lets only. Fig. 1. Platelet aggregation in normal and uremic platelet-rich plasma
(PRP). Platelet aggregation in response to 5 mm adenosine diphosphateIn each experiment, one sample was stained with
(ADP) was quantitated by the area under the aggregation curve fromFITC-conjugated, isotype-matched, nonspecific mouse zero to three minutes. One hundred percent aggregation was defined
immunoglobulin as a negative control. Another sample as maximum aggregation in normal PRP during titration with 0 to
20 mm ADP. Platelet aggregation decreased by 41% in uremic PRPwithout the addition of conjugated antibody served as
compared with normal PRP (*P , 0.05, N 5 9 each).an autofluorescence control. Fluorescence intensity was
measured with FACScan flow cytometer and was ana-
lyzed with CellQuest 3.1 software (Becton Dickinson).
Quantum fluorescence microbeads (calibrite beads; Bec- as mean 6 sd. A P value of less than 0.05 was considered
ton Dickinson) were used each day for standardization statistically significant.
of instrument settings.
Inhibition of fibrinogen binding to activated normal RESULTS
platelets by fibrinogen fragments Comparison between normal and uremic
Fibrinogen (Calbiochem-Novabiochem) was labeled platelet-rich plasma
with Na125I (Amersham Corp., Arlington Heights, IL,
Observations summarized in Figure 1 confirmed thatUSA) using the Iodogen method (Pierce Chemical
platelet aggregation in uremic PRP was less (by 41%)Corp., Rockford, IL, USA) [14]. The specific activity of
than that in normal PRP under identical test conditionsthe labeled protein was 1.4 3 105 cpm/mg. GFP was
(P , 0.05). Similarly, flow cytometric analysis with FITC-incubated with 125I-fibrinogen (0.1 mg/ml), ADP (10 mm),
conjugated activation-independent monoclonal antibodyand CaCl2 (0.2 mm) in the presence of gel-filtered fibrin- to GP IIIa (anti-CD61) indicated a 25% lower expressionogen fragments (4 mg/ml) or PBS in a total reaction
of GP IIIa on resting platelets from uremic patients com-volume of 100 ml at 228C for 30 minutes. After the incuba-
pared with normal resting platelets (P , 0.05; Fig. 2).tion, platelets with bound 125I-fibrinogen were separated
from the free 125I-fibrinogen by centrifugation at 5000 3 g Analysis of a-chymotrypsin–digested
for five minutes at 228C through a 20% sucrose gradient. fibrinogen fragments
The radioactivity associated with the platelets (total bind-
Fibrinogen fragments were prepared by proteolyticing) was then counted in a gamma-scintillation spectrome-
digestion of human fibrinogen with a-chymotrypsin, fol-ter (Minaxi g; Packard Instrument Co., Downers Grove,
lowed by the removal of intact fibrinogen using gel filtra-IL, USA). Nonspecific binding was determined in parallel
tion chromatography in some preparations. SDS-PAGEexperiments by adding a 100-fold molar excess of unla-
analysis showed that fibrinogen had been digested tobeled fibrinogen to the 125I-fibrinogen. Specific binding
fragments with molecular weights primarily between 90of 125I-fibrinogen to GFP was calculated by subtracting
and 120 kDa and, to a less extent, of approximately 45the nonspecific binding from the total binding. Nonspe-
kDa and less than 22 kDa (Fig. 3, lane 2). The smallcific binding was always less than 7% of the total binding.
amount of fragments with molecular weights of more
Statistical analysis than 120 kDa (appearing faintly in Fig. 3, lane 2) was
removed, along with the intact fibrinogen when gel fil-Statistical analysis was performed using unpaired or
paired Student’s t-test as appropriate. Data are expressed tration was applied (Fig. 3, lane 3). Other fragments with
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Fig. 2. Flow cytometric analysis of glycoprotein (GP) IIIa on resting
normal and uremic platelets. The expression of GP IIIa on resting
platelets from normal subjects and uremic patients was analyzed by
flow cytometry using an activation-independent anti-GP IIIa antibody
(anti-CD61). The expression of GP IIIa on resting uremic platelets
decreased by 25% compared with resting normal platelets (*P , 0.05,
N 5 7 each).
molecular weights of less than 10 kDa would have been
filtered through the Amicon PM-10 membrane and also
lost from the fragment preparation. Fractions containing
fragments with molecular weights either more than 120
kDa or less than 10 kDa had no activity against platelet
function or expression of platelet surface receptors GP
IIb-IIIa (data not shown). Fig. 3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis of chymotrypsin-digested fibrinogen fragments.
SDS-PAGE was performed using 10% gels under nonreducing condi-Effect of fibrinogen fragments on aggregation of
tions. Lane 1 contains fibrinogen (Mr 5 340 kDa). Lane 2 containsnormal platelets chymotrypsin-digested fibrinogen fragments prior to gel filtration. The
major fragments have a molecular radius (Mr) between 90 and 120 kDa,Figure 4 shows the effect of fibrinogen fragments on
although there are minor fragments with a Mr of approximately 45 kDaplatelet aggregation in normal PRP and GFP in response and less than 22 kDa; in addition, there is diffuse faint staining between
to the minimal dose of ADP required to produce maxi- the 116 and 200 kDa markers. Lane 3 contains chymotrypsin-digested
fibrinogen fragments after the removal of intact fibrinogen and largermal aggregation. Aggregation studies on PRP were per-
fragments by gel filtration and removal of small fragments (less thanformed using fibrinogen fragments (2.5 mg/ml) that in- 10 kDa) by membrane filtration during the concentration of the sample.
cluded intact fibrinogen (Fig. 3, lane 2), whereas studies Each lane contained 50 mg of protein.
on GFP were performed using a fibrinogen fragment
preparation (2.0 mg/ml) that had been depleted of intact
fibrinogen. Fibrinogen fragments decreased platelet ag-
clonal antibody against platelet surface GP IIIa (anti-gregation in PRP by 69 6 7% (P , 0.05). Aggregation
CD61) was used. The mean fluorescence intensity ofstudies on GFP were performed using fibrinogen frag-
anti-CD61 decreased by 29 6 10% (P , 0.05) on normalments depleted of intact fibrinogen (Fig. 3, lane 3). These
platelets that had been exposed to fibrinogen fragmentsfragments decreased platelet aggregation in GFP by 33 6
compared with control platelets (Fig. 5A). The expres-14% (P , 0.05).
sion of GP IIb-IIIa on ADP-activated normal platelets
Effect of fibrinogen fragments on the expression of was analyzed using FITC-conjugated activation-depen-
fibrinogen receptors on normal platelets dent monoclonal antibody against GP IIb-IIIa (PAC-1).
Platelets exposed to fibrinogen fragments were activatedTo quantitate the expression of GP IIIa on resting
platelets, FITC-conjugated activation-independent mono- with ADP, and the binding of PAC-1 was quantitated.
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Fig. 4. Effect of fibrinogen fragments on adenosine diphosphate
(ADP)-induced aggregation of normal platelets. After incubation with
either saline or fibrinogen fragments (2.5 mg/ml) generated by chymo-
trypsin digestion, platelet aggregation in normal platelet-rich plasma
(PRP) was induced by ADP. Experiments were also performed using
gel-filtered platelets (GFP) instead of PRP in an identical manner,
with the exception that a fibrinogen fragment preparation (2.0 mg/ml)
depleted of intact fibrinogen was used. Saline control is arbitrarily
defined as 100%. Fibrinogen fragments decreased platelet aggregation
in PRP by 69 6 7% (*P , 0.05 fibrinogen fragments vs. saline, N 5 5
each) and in GFP by 33 6 14% (*P , 0.05, fibrinogen fragments vs.
saline, N 5 7 each).
Fibrinogen fragments decreased the binding of PAC-1
on the surface of ADP-activated platelets by 42 6 19%
Fig. 5. Effect of fibrinogen fragments on glycoprotein (GP) IIb-IIIa
(P , 0.05) compared with controls (Fig. 5B). expression on normal platelets. (A) GP IIIa on resting normal platelets.
After normal platelets were incubated with phosphate-buffered saline
or gel-filtered fibrinogen fragments, flow cytometric analysis was per-Effect of fibrinogen fragments on fibrinogen binding
formed using FITC-conjugated activation-independent monoclonal an-to activated normal platelets
tibody against platelet surface GP IIIa (anti-CD61). The expression of
GP IIIa on resting platelets decreased by 29 6 10% after exposure toPlatelets incubated with 125I-fibrinogen in the presence
fibrinogen fragments (*P , 0.05, N 5 7 each). (B) GP IIb-IIIa complexor absence of fibrinogen fragments were activated with
on ADP-activated normal platelets. After normal platelets were incu-
ADP. Fibrinogen fragments decreased the specific bind- bated with phosphate-buffered saline or gel-filtered fibrinogen frag-
ments, they were activated with ADP, and flow cytometric analysis wasing of 125I-fibrinogen to activated normal platelets by
performed using FITC-conjugated activation-dependent monoclonal92 6 2% (P , 0.001; Fig. 6).
antibody against platelet surface GP IIb-IIIa (PAC-1). Expression of
activated GP IIb-IIIa on platelets decreased by 42 6 19% after exposure
to fibrinogen fragments (*P , 0.05, N 5 7 each).
DISCUSSION
This study confirms that uremic platelets are less re-
sponsive to ADP than normal platelets as noted pre-
ogen fragments may occupy a percentage of the plateletviously [4, 5]. Because fibrinogen fragments have been
surface fibrinogen receptors, thus preventing the bindingsuggested to contribute to uremic platelet dysfunction
of fibrinogen to platelets, a step considered to be essen-[11], the effect of fragments obtained from chymotrypsin
tial for aggregation [11]. A decreased availability ofdigestion of fibrinogen on platelet function was investi-
platelet fibrinogen receptors in the presence of fibrino-gated. This study clearly demonstrates that fibrinogen
gen fragments, as determined by reduced binding of anti-fragments decrease platelet aggregation in normal PRP
CD61 (Fig. 5A), supports this hypothesis.as well as in isolated normal platelets (Fig. 4).
In addition to its up-regulation, a change in the confor-Confirming previous reports [11, 15–17], we also found
mation of the fibrinogen receptor GP IIb-IIIa is impor-a decreased expression of fibrinogen binding sites on
tant for platelet aggregation [10, 18]. To further substan-resting uremic platelets compared with normal platelets,
tiate the hypothesis that fibrinogen fragments interfereas measured by reduced binding of an activation-inde-
with fibrinogen receptors during platelet activation,pendent monoclonal antibody against platelet GP IIIa
(anti-CD61; Fig. 2). It has been hypothesized that fibrin- binding of an activation-dependent anti-human platelet
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120 kDa, these data clearly demonstrate that fibrinogen
fragments are capable of impairing platelet aggregation
and suggest a role of similar fragments in the pathogene-
sis of uremic platelet dysfunction.
Therefore, it will be of considerable interest to study
the effects of endogenous fibrinogen fragments con-
tained in uremic plasma on platelet function. Further
studies will also be required to investigate the amino
acid sequence of fibrinogen fragments involved and to
elucidate the precise mechanism by which fibrinogen
fragments may suppress platelet function in uremic pa-
tients.
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